603207.SHG XIAO FANG ORD A (SHH) EQSW Exp:
- Market cap
- CNY 3.71B
- P/E
- 19.3x
- P/B
- 3.21x
- ROE
- 18.3%
- Dividend yield
- 9.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603207.SHG undervalued?
Graham number603207.SHG trades 65.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XIAO FANG ORD A (SHH) EQSW Exp: fundamental analysis
No fundamental analysis for XIAO FANG ORD A (SHH) EQSW Exp: yet.
XIAO FANG ORD A (SHH) EQSW Exp: stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XIAO FANG ORD A (SHH) EQSW Exp:
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. produces and sells medicines in China and internationally. It offers medicines in the areas of gastroenterology, dermatology, orthopedics, ENT, and disinfection. It also engages in the family health management business. The company was founded in 1993 and is based in Shanghai, China.
Full company profileXIAO FANG ORD A (SHH) EQSW Exp: financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XIAO FANG ORD A (SHH) EQSW Exp: annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 402M | 457M | 472M | 475M | 525M | 568M |
| Gross Profit | 255M | 270M | 309M | 311M | 341M | 341M |
| Operating Income | 151M | 204M | 233M | 234M | 240M | 234M |
| EBITDA | - | 210M | 240M | 242M | 244M | 241M |
| Net Income | 126M | 175M | 204M | 205M | 207M | 207M |
| EPS | 1.05 | 1.46 | 1.70 | 1.28 | 1.29 | 1.28 |
| Balance Sheet | ||||||
| Total Assets | 386M | 463M | 713M | 1.40B | 1.24B | 1.31B |
| Total Liabilities | 157M | 90.9M | 133M | 168M | 147M | 174M |
| Shareholders' Equity | 229M | 372M | 580M | 1.23B | 1.09B | 1.13B |
| Cash & Short-term Investments | 44.8M | 58.7M | 286M | 883M | 648M | 721M |
| Cash Flow | ||||||
| Operating Cash Flow | 180M | 137M | 200M | 212M | 161M | - |
| Capital Expenditure | 12.5M | 61.6M | 80.2M | 83.9M | 54.2M | 88.8M |
| Free Cash Flow | 167M | 75.6M | 120M | 128M | 107M | 141M |
| Ratios | ||||||
| ROE | 55.1% | 47.0% | 35.1% | 16.6% | 19.0% | 18.3% |
| ROA | 32.7% | 37.8% | 28.6% | 14.6% | 16.7% | 15.9% |
| Net Profit Margin | 31.4% | 38.3% | 43.2% | 43.3% | 39.5% | 36.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
XIAO FANG ORD A (SHH) EQSW Exp: dividends
- Dividend yield
- 9.51%
- Forward dividend
- 0.76 CNY
- Payout ratio
- 170.2%
- Ex-dividend date
- Oct 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 353M | 2.20 | 170.2% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | CNY 111M | 0.93 | 63.6% |
| 2021 | CNY 84.6M | 0.70 | 67.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns XIAO FANG ORD A (SHH) EQSW Exp:
- Insiders 70.71%
- Institutions 1.33%
- Public & others 27.96%
- Shares outstanding 162M
- Free float 52.8M
XIAO FANG ORD A (SHH) EQSW Exp: company profile
- Company name
- XIAO FANG ORD A (SHH) EQSW Exp:
- Ticker
- 603207.SHG
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 529
- Fiscal year end
- December
- Address
- No. 777 Hongzhu Road, Shanghai, China, 201411
- Phone
- 86 21 5820 7999
- Website
- xf-pharma.com
About XIAO FANG ORD A (SHH) EQSW Exp:
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. produces and sells medicines in China and internationally. It offers medicines in the areas of gastroenterology, dermatology, orthopedics, ENT, and disinfection. It also engages in the family health management business. The company was founded in 1993 and is based in Shanghai, China.
XIAO FANG ORD A (SHH) EQSW Exp: management
10- Mr. Zhiguang FangGM & Chairman · born 1957
- Ms. Xiaoxu LuoDeputy GM, CFO, Secretary & Director · born 1989
- Ms. Juan XuFinancial Manager & Accounting Supervisor · born 1981
- Mr. Yufeng YinMarketing Manager & Director · born 1979
- Mr. Jiachen FangDeputy GM & Director · born 1988
- Mr. Yunfei ZhaoChief Engineer · born 1977
- Ms. Ying CaoDeputy General Manager · born 1983
- Ms. Lili JiangAssistant to the Chairman · born 1986
- Ms. Ai'e JiangDeputy Factory Manager & Production Director · born 1978
- Mr. Zouqing YaoAssistant to the Chairman · born 1983